MCQ
Drugs regulation and child safety MCQ - Practice Questions with Answers
Solve 1 Drugs regulation and child safety questions for RAS/RPSC preparation.
Practice questions
Q1With reference to the prohibition on chlorpheniramine maleate–phenylephrine hydrochloride combinations for young children, consider the following statements: 1. The prohibition covers only a few selected fixed-dose combinations containing both ingredients, not all such formulations. 2. The decision followed recommendations from an expert committee and the Drugs Technical Advisory Board. 3. Manufacturers are not required to display any warning on labels or promotional material. Which of the statements given above is/are correct?
All fixed-dose combinations containing both ingredients are prohibited for use in children below four years, so statement 1 is incorrect. The decision followed expert committee and Drugs Technical Advisory Board recommendations, so statement 2 is correct. Manufacturers must display the prescribed warning on labels, package inserts and promotional material, so statement 3 is incorrect. Hence only statement 2 is correct.
You've seen 1 of 1 sample questions
Unlimited practice on Drugs regulation and child safety comes with the RAS Test Series + Practice pack or Gate Pass.
